US FDA draft guideline seeks to foster drug development for chronic fatigue syndrome

The US Food and Drug Administration has released a draft guidance to help drug sponsors develop treatments for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), a condition for which there are currently no FDA-approved medicines1,2.